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The risk of stroke is five-folds higher among patients with atrial fibrillation (AF) in 
comparison to those without AF. In fact, thromboembolic strokes occurring in AF 
patients are more disabling and fatal than in patients without AF. This increase in 
morbidity and mortality due to stroke in patients with atrial fibrillation has become a 
major global healthcare burden, and for this reason stroke prevention (using 
antithrombotic agents as the mainstay therapy) has been a critical feature of AF 
management. Although warfarin (an oral vitamin K antagonist) has been traditionally 
used for preventing stroke in AF patients, its complex pharmacology (i.e., narrow 
therapeutic index requiring regular therapeutic monitoring, its interactions with food, 
alcohol, and othe  medica i n ), and e c ibe  c nce n  ega ding a ien  
nonadherence to the therapy make the decision-making around the initiation of therapy 
i e c m lica ed. C n e en l , an ic ag lan  a e nde ili ed in man  a - i k  
patients, exposing them to an increased risk of a preventable stroke. Our research in a 
hospital-based study that used decision-making support tool i.e., a computerised 
antithrombotic risk assessment tool (CARAT- a tool developed based on local and 
international guidelines assis  in he a  elec i n ba ed n a ien  indi id ali ed i k 
versus benefit assessment) observed a marginal increase in anticoagulation prescription 
among eligible patients (57.8% vs 64.7%, P=0.35) in comparison to the baseline 
prescription. However, many at-risk patients were still not prescribed anticoagulants as 
ec mmended b  CARAT, and he clinician  ag eemen  i h CARAT ec mmenda i n 
a  l . Thi  migh  ha e been d e  clinician  e cei ed fea  f i k ch a  fall , 
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bleeding, and a ien  n nadhe ence  he he a . T  inc ea e clinician  acce ance 
for CARAT tool, studies should further explore its validity in predicting clinical outcomes. 
 
Recently, the direct oral anticoagulants (DOACs) have become available for 
thromboprophylaxis in patients with AF. These agents have safety and efficacy (in stroke 
prevention) profiles comparable to warfarin therapy. They also offer some practical 
advantages over warfarin in terms of not requiring regular therapeutic drug monitoring, 
plus their interactions with food, alcohol and other medications is limited. However, the 
DOACs are not completely devoid of risks or challenges to their use. These challenges 
include: a) the lack of specific drug monitoring tests; b) complicated management of 
renally-impaired patients; c) limited access to and/or unavailability of antidotes for the 
management of DOAC- ela ed ac e bleeding; d) high -of- cke  c  f  a ien  
in some countries; and e) the potential for patient nonadherence (due to the more frequent 
dosing required with dabigatran and apixaban). Such conditions present specific 
challenges for clinicians when prescribing these medications for long-term stroke 
prophylaxis in patients with AF. In 2014 following the listing of DOACs on the 
pharmaceutical benefits scheme (PBS) (which subsidises DOACs for stroke prevention 
in AF), it was important to report their utilisation of anticoagulant prescription in local 
Australian settings. It was also necessary to updated CARAT 2.0 in assessing whether the 
prescriptions were based on these revised guidelines. Our study (in a hospital setting in 
Sydney) found that 52.0% of the people were prescribed anticoagulants. Warfarin was 
the first-choice anticoagulant prescribed for two-thirds of patients, while the remaining 
one-third were on DOCAs. However, most of the patients eligible for anticoagulants were 
not prescribed it but were either prescribed antiplatelets or kept on nil therapy. 
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In hi  he i  a c ed li e a e e ie  e l ed fac  infl encing a ien  
preference and adherence for warfarin versus DOACs. This is because research suggests 
that patients have an important role in the decision-making process for antithrombotic 
he a  elec i n in AF. Thi  e ie  di c ed a ien  e ec i e  n medica i n . 
Here the findings were synthesised to present a framework depicting the five interacting 
dimensions of adherence: 1) therapy-related factors; 2) patient-related factors; 3) 
condition-related factors; 4) social economic factors; and 5) health system factors. From 
hi  d , i  a  clea  ha  a ien  ie  ab  ea men  m  be inc a ed in  he 
decision-making process to facilitate a) treatment; b) adherence; and c) achieve good 
clinical outcomes. In line with this study, another study then evaluated the information 
within web-based resources designed to educate patients on thromboprophylaxis in AF. 
The content and thematic analysis were conducted on these resources. It was found that 
the information provided in these resources were varied. It was found that implied bias 
of some resources towards specific anticoagulant therapies and their imbalanced 
information on the importance of anticoagulation in AF might misinform or confuse 
a ien . The ef e, a ien  engagemen  in ha ed deci i n-making and adherence to 
medicines might be undermined by the suboptimal quality of information provided in 
these resources.  
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ACC American College of Cardiology  
AF Atrial Fibrillation 
AHA American Heart Association 
CARAT Computerised Antithrombotic Risk 
Assessment Tool 
CCF Congestive Cardiac Failure 
CI Confidence Interval/s 
DOACs Direct Oral Anticoagulants 
DST Decision Support Tool/s 
ESC European Society of Cardiology 
FDA Food and Drug Administration 
HRS Heart Rhythm Society 
Hx History 
NICE National Institute for Health and Care 
Excellence 
NOACs Novel/ New Oral Anticoagulants OR 
Non-Vitamin K Antagonist Oral 
Anticoagulants 
Word NOACs was used only in journal 
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DOACs Direct Oral Anticoagulants 
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Word DOACs is used throughout the 
thesis expected in some articles 
NSAIDs Non-steroidal anti-inflammatory drugs 
NVAF Non-valvular atrial fibrillation 
NSW New South Wales  
QoL Quality of Life 
OR Odds Ratio 
PBS Pharmaceutical Benefits Scheme 
SDM Shared Decision-Making 
SPSS Statistical Software for Social Sciences 
TAG Therapeutic Advisory Group 
TIA Transient Ischemic Attack 
TM Trademark 
Tx Therapy/ Treatment 
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